Form 4: BioLargo Chief Science Officer Converts Debt to Equity, Boosts Stake
Insider Transaction Report
BioLargo, Inc.'s Chief Science Officer, Kenneth Reay Code, acquired 181,253 shares of common stock by converting outstanding salary and expense obligations into equity at $0.2 per share, increasing his total beneficial ownership to over 25 million shares.
Summary
- Kenneth Reay Code, BioLargo, Inc.'s Chief Science Officer, Director, and 10% Owner, acquired 181,253 shares of common stock.
- The acquisition occurred on July 14, 2025, at a price of $0.2 per share.
- The shares were received in exchange for a reduction in amounts owed by BioLargo to Mr. Code for salary and unreimbursed business expenses.
- Following this transaction, Mr. Code beneficially owns a total of 25,131,495 shares, including 22,139,012 shares held indirectly through a wholly-owned corporation.
Sentiment
Score: 6
Explanation: While the debt-for-equity swap suggests cash conservation, the insider's willingness to accept shares and increase their stake is a positive sign of confidence. The overall sentiment is moderately positive due to insider alignment, despite the underlying reason for the conversion.
Positives
- Increases insider ownership, aligning management's interests with shareholders.
- Reduces the company's outstanding liabilities (salary and expense obligations) by converting them into equity.
- Demonstrates confidence by a key officer in the company's future by accepting shares instead of cash for owed amounts.
Negatives
- The conversion of debt to equity at $0.2 per share might indicate a need for the company to conserve cash or that the company's stock is trading at a low valuation.
- Dilution of existing shareholders, albeit minor for this specific transaction, as new shares are issued.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Kenneth Reay Code granted a Limited Power of Attorney to John R. Browning for Section 16 reporting obligations, allowing him to execute and file Forms 3, 4, and 5 on Mr. Code's behalf. | February 14, 2017 | Streamlines compliance with SEC reporting requirements for insider transactions. |
Related Party Transactions
- The acquisition of shares by Kenneth Reay Code, an officer and director, in exchange for salary and unreimbursed business expenses owed by the Issuer, constitutes a related party transaction.
Stakeholder Impact
- Shareholders: Potential minor dilution from the issuance of new shares, but also increased alignment of management interests with shareholders.
- Creditors: Reduction in outstanding liabilities (debt owed to Mr. Code), which could be viewed positively.
- Employees (specifically Mr. Code): Compensation received in equity rather than cash, indicating a commitment to the company's long-term value.
Key Dates
| Date | Description |
|---|---|
| February 14, 2017 | Date Kenneth Reay Code granted Limited Power of Attorney to John R. Browning for Section 16 reporting obligations. |
| July 14, 2025 | Date of the common stock acquisition transaction by Kenneth Reay Code. |
| July 16, 2025 | Date the Form 4 was signed by John R. Browning, attorney-in-fact for Kenneth Reay Code. |
Recommendation
holdKeywords
BioLargo, BLGO, SEC Form 4, Insider Trading, Equity Conversion, Debt to Equity, Kenneth Reay Code, Chief Science Officer, Share Acquisition, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.